January 28, 2021 -- Provention Bio has released results from a preclinical proof-of-concept study for its bispecific antibody-based molecule, PRV-3279, conducted in mouse models for Pompe disease.
PRV-3279 is a dual-affinity retargeting (DART) molecule, targeting the B-cell surface proteins CD32B and CD79B. Simultaneous engagement of these receptors, triggers inhibition of B-cell function and suppression of autoantibody production, thereby regulating B cells without causing depletion
In the study, transgenic mice received gene therapy with an adeno-associated virus 9 (AAV9) vector encoding for the enzyme acid-alpha-glucosidase (GAA) gene. Errors in the GAA gene cause Pompe disease. PRV-3279 reduced anti-AAV9 vector antibody levels in a dose-dependent manner. Coadministration of PRV-3279 with gene therapy has the potential to improve the safety and efficacy of gene therapy treatments, according to the firm.
"We believe PRV-3279 has the potential to intercept and prevent the immunogenicity of life-saving gene therapy products and other biotherapeutics," stated Ashleigh Palmer, CEO and co-founder, Provention Bio.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
